Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus

Thomas Geisbert, Joan B. Geisbert, Anders Leung, Kathleen M. Daddario-DiCaprio, Lisa E. Hensley, Allen Grolla, Heinz Feldmann

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccine consisting of equal parts of the vaccine vectors VSVΔG/SEBOVGP, VSVΔG/ZEBOVGP, and VSVΔG/MARVGP. Four weeks later, three of these animals were challenged with MARV, three with CIEBOV, three with ZEBOV, and two with SEBOV. Three control animals were vaccinated with VSV vectors encoding a nonfilovirus GP and challenged with SEBOV, ZEBOV, and MARV, respectively, and five unvaccinated control animals were challenged with CIEBOV. Importantly, none of the macaques vaccinated with the blended vaccine succumbed to a filovirus challenge. As expected, an experimental control animal vaccinated with VSVΔG/ZEBOVGP and challenged with SEBOV succumbed, as did the positive controls challenged with SEBOV, ZEBOV, and MARV, respectively. All five control animals challenged with CIEBOV became severely ill, and three of the animals succumbed on days 12, 12, and 14, respectively. The two animals that survived CIEBOV infection were protected from subsequent challenge with either SEBOV or ZEBOV, suggesting that immunity to CIEBOV may be protective against other species of Ebola virus. In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species.

Original languageEnglish (US)
Pages (from-to)7296-7304
Number of pages9
JournalJournal of Virology
Volume83
Issue number14
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Tai Forest ebolavirus
Sudan Ebola virus
Marburg virus
Marburgvirus
Ebolavirus
Zaire Ebola virus
Filoviridae
Primates
Vaccines
vaccines
injection
Injections
Vesiculovirus
Infection
infection
Cote d'Ivoire
animals
Sudan
glycoproteins
Democratic Republic of the Congo

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Geisbert, T., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009). Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. Journal of Virology, 83(14), 7296-7304. https://doi.org/10.1128/JVI.00561-09

Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. / Geisbert, Thomas; Geisbert, Joan B.; Leung, Anders; Daddario-DiCaprio, Kathleen M.; Hensley, Lisa E.; Grolla, Allen; Feldmann, Heinz.

In: Journal of Virology, Vol. 83, No. 14, 07.2009, p. 7296-7304.

Research output: Contribution to journalArticle

Geisbert, T, Geisbert, JB, Leung, A, Daddario-DiCaprio, KM, Hensley, LE, Grolla, A & Feldmann, H 2009, 'Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus', Journal of Virology, vol. 83, no. 14, pp. 7296-7304. https://doi.org/10.1128/JVI.00561-09
Geisbert, Thomas ; Geisbert, Joan B. ; Leung, Anders ; Daddario-DiCaprio, Kathleen M. ; Hensley, Lisa E. ; Grolla, Allen ; Feldmann, Heinz. / Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. In: Journal of Virology. 2009 ; Vol. 83, No. 14. pp. 7296-7304.
@article{ec6f302c13dd476caf288781649996a2,
title = "Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus",
abstract = "The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccine consisting of equal parts of the vaccine vectors VSVΔG/SEBOVGP, VSVΔG/ZEBOVGP, and VSVΔG/MARVGP. Four weeks later, three of these animals were challenged with MARV, three with CIEBOV, three with ZEBOV, and two with SEBOV. Three control animals were vaccinated with VSV vectors encoding a nonfilovirus GP and challenged with SEBOV, ZEBOV, and MARV, respectively, and five unvaccinated control animals were challenged with CIEBOV. Importantly, none of the macaques vaccinated with the blended vaccine succumbed to a filovirus challenge. As expected, an experimental control animal vaccinated with VSVΔG/ZEBOVGP and challenged with SEBOV succumbed, as did the positive controls challenged with SEBOV, ZEBOV, and MARV, respectively. All five control animals challenged with CIEBOV became severely ill, and three of the animals succumbed on days 12, 12, and 14, respectively. The two animals that survived CIEBOV infection were protected from subsequent challenge with either SEBOV or ZEBOV, suggesting that immunity to CIEBOV may be protective against other species of Ebola virus. In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species.",
author = "Thomas Geisbert and Geisbert, {Joan B.} and Anders Leung and Daddario-DiCaprio, {Kathleen M.} and Hensley, {Lisa E.} and Allen Grolla and Heinz Feldmann",
year = "2009",
month = "7",
doi = "10.1128/JVI.00561-09",
language = "English (US)",
volume = "83",
pages = "7296--7304",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "14",

}

TY - JOUR

T1 - Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus

AU - Geisbert, Thomas

AU - Geisbert, Joan B.

AU - Leung, Anders

AU - Daddario-DiCaprio, Kathleen M.

AU - Hensley, Lisa E.

AU - Grolla, Allen

AU - Feldmann, Heinz

PY - 2009/7

Y1 - 2009/7

N2 - The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccine consisting of equal parts of the vaccine vectors VSVΔG/SEBOVGP, VSVΔG/ZEBOVGP, and VSVΔG/MARVGP. Four weeks later, three of these animals were challenged with MARV, three with CIEBOV, three with ZEBOV, and two with SEBOV. Three control animals were vaccinated with VSV vectors encoding a nonfilovirus GP and challenged with SEBOV, ZEBOV, and MARV, respectively, and five unvaccinated control animals were challenged with CIEBOV. Importantly, none of the macaques vaccinated with the blended vaccine succumbed to a filovirus challenge. As expected, an experimental control animal vaccinated with VSVΔG/ZEBOVGP and challenged with SEBOV succumbed, as did the positive controls challenged with SEBOV, ZEBOV, and MARV, respectively. All five control animals challenged with CIEBOV became severely ill, and three of the animals succumbed on days 12, 12, and 14, respectively. The two animals that survived CIEBOV infection were protected from subsequent challenge with either SEBOV or ZEBOV, suggesting that immunity to CIEBOV may be protective against other species of Ebola virus. In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species.

AB - The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccine consisting of equal parts of the vaccine vectors VSVΔG/SEBOVGP, VSVΔG/ZEBOVGP, and VSVΔG/MARVGP. Four weeks later, three of these animals were challenged with MARV, three with CIEBOV, three with ZEBOV, and two with SEBOV. Three control animals were vaccinated with VSV vectors encoding a nonfilovirus GP and challenged with SEBOV, ZEBOV, and MARV, respectively, and five unvaccinated control animals were challenged with CIEBOV. Importantly, none of the macaques vaccinated with the blended vaccine succumbed to a filovirus challenge. As expected, an experimental control animal vaccinated with VSVΔG/ZEBOVGP and challenged with SEBOV succumbed, as did the positive controls challenged with SEBOV, ZEBOV, and MARV, respectively. All five control animals challenged with CIEBOV became severely ill, and three of the animals succumbed on days 12, 12, and 14, respectively. The two animals that survived CIEBOV infection were protected from subsequent challenge with either SEBOV or ZEBOV, suggesting that immunity to CIEBOV may be protective against other species of Ebola virus. In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species.

UR - http://www.scopus.com/inward/record.url?scp=67650383786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650383786&partnerID=8YFLogxK

U2 - 10.1128/JVI.00561-09

DO - 10.1128/JVI.00561-09

M3 - Article

C2 - 19386702

AN - SCOPUS:67650383786

VL - 83

SP - 7296

EP - 7304

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 14

ER -